Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies
Sara M. Radwan, Dina Mostafa, Rania A. Radwan, Hany A. Elghobary, Wesam R. Elghamry, Amany M. Kamal · 2026
Read Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies by Sara M. Radwan, Dina Mostafa, Rania A. Radwan, Hany A. Elghobary, Wesam R. Elghamry, Amany M. Kamal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13251009.txt.
Description
Radwan and co-authors test two cell-death genes as early warning markers in acute myeloid leukemia. Their 2026 BMC Cancer study compares samples from one hundred newly diagnosed patients with forty healthy volunteers. Five-year survival in this leukemia stays poor, and relapse often grows from cells that dodge normal death programs.
One gene, NFS1, ran high in patients, while GSDMD ran low, and both patterns reversed after treatment. Worse starting patterns, high NFS1 with low GSDMD, marked patients with poorer outlooks and lower one-year survival. The genes tie to two newer death routes, ferroptosis and pyroptosis, that cancer cells often suppress. The authors propose the pair as diagnostic and prognostic markers and as possible treatment targets.
Catalog record
| CREATOR | Sara M. Radwan, Dina Mostafa, Rania A. Radwan, Hany A. Elghobary, Wesam R. Elghamry, Amany M. Kamal |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |